As far as I know, no. It is an interesting topic that has come up before and one I think has a lot of potential. The issue is it is generally not a good idea to take a new drug using a new delivery mechanism to the regulatory agencies for approval unless you really, really need to do this - they just don’t like too much novelty all at once.
The better way to approach these things is get approval using conventional formulation approaches and then later extend by developing new formulations.
Ann: Expanded Heart Protection Discovery for Zantrene, page-294
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |